Position in EXEL
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$473,802
+$73,553 QoQ
Shares Held
8,708
-6.7% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#440
of 754 holders
Holding Since
Dec 2021
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Motley Fool Asset Management LLC holds $16,682,515 across 10 Biotechnology names. EXEL ranks #5 (2.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
17,288 | $8,587,468 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
9,170 | $2,760,445 | |
| 3 | RARE |
Ultragenyx Pharmaceutical Inc.
|
70,651 | $2,359,036 | |
| 4 | ADMA |
Adma Biologics, Inc.
|
91,041 | $762,013 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
8,708 | $473,802 | |
| 6 | MRNA |
Moderna, Inc.
|
6,721 | $470,671 | |
| 7 | AXSM |
Axsome Therapeutics, Inc.
|
1,551 | $379,638 | |
| 8 | INCY |
Incyte Corp
|
3,291 | $373,067 |
All Filings in EXEL
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $473,802 | 8,708 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $400,249 | 9,332 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $386,405 | 8,816 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $341,922 | 8,279 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $379,088 | 8,600 | Shares | Sole | 2025-08-01 | |
| 2025-03-31 | $285,945 | 7,745 | Shares | Sole | 2025-05-12 | |
| 2024-12-31 | $223,309 | 6,706 | Shares | Sole | 2025-02-12 | |
| 2021-12-31 | $3,436 | 188 | Shares | Sole | 2022-02-10 | |
| No filing history on record for this holder in this stock. | ||||||